Clinical features of the 2 TMA subtypes of DLBCL
. | Total (%) . | GCB (%) . | Non-GCB (%) . | P . |
|---|---|---|---|---|
| Total no. | 152 | 64 | 88 | |
| Sex | ||||
| Male | 82 (54) | 29 (45) | 53 (60) | .11 |
| Female | 70 (46) | 35 (55) | 35 (40) | |
| Age, y | ||||
| Median | 63 | 60 | 64 | .56 |
| Range | 14-90 | 14-82 | 21-90 | |
| Stage | ||||
| I/II | 77 (51) | 32 (51) | 45 (51) | .97 |
| III/IV | 74 (49) | 31 (49) | 43 (49) | |
| Extranodal sites | ||||
| Fewer than 2 | 120 (82) | 48 (77) | 72 (85) | .36 |
| 2 or more | 27 (18) | 14 (23) | 13 (15) | |
| Karnofsky score | ||||
| Higher than 70 | 117 (77) | 51 (80) | 66 (76) | .51 |
| 70 or lower | 34 (23) | 13 (20) | 21 (24) | |
| LDH | ||||
| Normal | 65 (48) | 32 (56) | 33 (42) | .11 |
| High | 70 (52) | 25 (44) | 45 (58) | |
| IPI risk group | ||||
| Low, 0-2 | 84 (66) | 35 (65) | 49 (66) | .80 |
| High, 3-5 | 44 (34) | 19 (35) | 25 (34) |
. | Total (%) . | GCB (%) . | Non-GCB (%) . | P . |
|---|---|---|---|---|
| Total no. | 152 | 64 | 88 | |
| Sex | ||||
| Male | 82 (54) | 29 (45) | 53 (60) | .11 |
| Female | 70 (46) | 35 (55) | 35 (40) | |
| Age, y | ||||
| Median | 63 | 60 | 64 | .56 |
| Range | 14-90 | 14-82 | 21-90 | |
| Stage | ||||
| I/II | 77 (51) | 32 (51) | 45 (51) | .97 |
| III/IV | 74 (49) | 31 (49) | 43 (49) | |
| Extranodal sites | ||||
| Fewer than 2 | 120 (82) | 48 (77) | 72 (85) | .36 |
| 2 or more | 27 (18) | 14 (23) | 13 (15) | |
| Karnofsky score | ||||
| Higher than 70 | 117 (77) | 51 (80) | 66 (76) | .51 |
| 70 or lower | 34 (23) | 13 (20) | 21 (24) | |
| LDH | ||||
| Normal | 65 (48) | 32 (56) | 33 (42) | .11 |
| High | 70 (52) | 25 (44) | 45 (58) | |
| IPI risk group | ||||
| Low, 0-2 | 84 (66) | 35 (65) | 49 (66) | .80 |
| High, 3-5 | 44 (34) | 19 (35) | 25 (34) |
LDH indicates lactate dehydrogenase.